Due to the complexity of combination products, drug sponsors may receive several deficiencies and compliance observations—known as 483 observations in the United States. Part two of Adam Lambert’s article clarifies important guidance points to help mitigate the risk surrounding validation of methods and to ensure a robust marketing application.
Our unique approach can help your company navigate the complexities of launching a drug, biologic or medical device into multiple markets. The first step? Connecting. Simply fill out our form and a representative will follow-up shortly.
1.877.787.0177
510.732.0177
22320 Foothill Blvd. Suite 330, Hayward CA 94541
